Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Asuragen, a fully integrated molecular diagnostic company, has launched miRInform pancreas test for use on fine needle aspirate specimens of pancreatic masses.
Subscribe to our email newsletter
The miRInform Pancreas was developed to diagnose and manage pancreatic ductal adenocarcinoma (PDAC) when cytology is inconclusive.
Astudy showed that miRInform pancreas test was able to resolve over 75% of the FNAs that were indeterminate by cytology, which comprised approximately 13% of the samples in the study.
The pancreas test combined with positive FNA cytology resulted in an overall accuracy of 92.5% versus 80.6% for cytology alone.
Asuragen CEO Matt Winkler said that they believe miRNAs will prove to be highly relevant for many additional cancer diagnostic applications.